ClinicalTrials.gg
RecruitingNCT05606523EXTRAUpdated Dec 6, 2024

Microbiota and Pancreatic Cancer Cachexia

An observational study in Pancreatic Cancer, Microbiota and Cachexia, sponsored by Genton Graf Laurence. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by Genton Graf Laurence · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
24
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Pancreatic Neoplasms with a site in Switzerland — 9 open to participants now, 11 under way, 3 of them phase 3. Pancreatic Neoplasms · Switzerland.

Planned enrollment
9th of 10
24 · median 79
Started
2022
with 3 others
Observational
10 of 58
2 open now
Primary completion
2025-04
later than 1 of 10 live
Registered
47th of 58
by date

Among the 58 studies in Pancreatic Neoplasms with a site in Switzerland, this one is the 9th largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2022, is one of 10 observational ones, reaches primary completion later than 1 of the 10 other live ones, and was the 47th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

9 of the 58 studies in Pancreatic Neoplasms with a site in Switzerland are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Pancreatic Neoplasms with a site in Switzerland, or all of them as a file.
02

Study summary

This monocentric study aims at evaluating the effects of fecal microbiota transplantation from newly diagnosed cachectic and non-cachectic pancreatic cancer patients, and healthy volunteers on several cachexia-related parameters of germ-free mice.

Read the detailed description

Aim: Evaluating the effects of fecal microbiota transplantation (FMT) from 6 newly diagnosed cachectic and 6 non-cachectic pancreatic cancer patients, and 12 healthy age-and sex-matched volunteers on several cachexia-related parameters of 96 germ-free mice (4 per donor) over a 30-day period. The fecal material of all 12 pancreatic cancer patients will be collected at diagnosis before any cancer treatment onset.

Hypothesis: FMT of cachectic patients with pancreas cancer, naïve of any anti-cancer treatment and artificial nutrition, into germ-free mice impairs weight gain, in contrast to FMT of non-cachectic patients and healthy controls.

03

Conditions studied

  • Pancreatic Cancer
  • Microbiota
  • Cachexia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

We will consider the fecal samples of 12 patients at diagnosis of pancreatic cancer including 6 patients with cachexia and 6 patients without cachexia, and therefore naïve of any anti-cancer treatment and artificial nutritional support. We will also include 12 healthy volunteers matched for gender and age (± 5 years) with the pancreatic cancer patients.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with pancreatic cancer (n=12)

  • ≥18 years and
  • Newly diagnosed of pancreatic adenocarcinoma (local or ) and
  • Tube feeding or parenteral nutrition ≤ 14 days

Cachectic pancreatic cancer patients (n=6)

  • Cachexia according to the Fearon criteria 1: involuntary weight loss >5% over the last 6 months, or any level of weight loss >2% and a \<20 kg/m2 or sarcopenia. Sarcopenia will be diagnosed by BIA (fat-free mass index is \<17 kg/m2 in men and \<15 kg/m2 in women) 81, and not by CT, as it is faster and can be performed at the bedside of the patient. Non-cachectic pancreatic cancer patients (n=6)
  • Normal nutritional state: weight stability (± 2% of habitual weight) over the last 6 months, no anorexia before the diagnosis (appetite rating on a visual analogue scale of 100mm), no known impaired glucose tolerance.

Healthy matched subjects (n=12)

  • ≥18 years and
  • BMI between 18.5 and 30 kg/m2 and
  • Absence of chronic or acute disease and
  • Matching for gender and age (± 5 years) with an included pancreatic cancer patient

Exclusion criteria

Exclusion Criteria:

  • \< 18 years or
  • Inability to give consent or
  • Insufficient knowledge of project language (French, German) or
  • Pancreatic adenocarcinoma already treated by chemo- or radiotherapy, or major surgery as duodenopancreatectomy or biliary diversion
  • Known rheumatologic or immunologic diseases
  • Therapeutic antibiotics or drugs (for instance , cytostatics, antibodies) in the 30 days preceding the inclusion
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
24 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Cachectic patients with pancreatic cancer

    Measurements and sample collection at one timepoint.

  • Non-cachectic patients with pancreatic cancer

    Measurements and sample collection at one timepoint.

  • Healthy volunteers

    Measurements and sample collection at one timepoint.

06

What researchers measure

Primary outcomes

  1. Body weight changes in mice after fecal material transplantation.

    Body weight (g)

    Time frame: Between days 0 and 30

Secondary outcomes

  1. Differences in fecal microbiota

    by 16S rRNA gene amplicon sequencing and functional profiles by metagenomic sequencing between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  2. Body weight

    in kilograms between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  3. Waist-to-hip ratio

    waist circumference (cm) and hip circumference (cm) between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  4. Fat mass

    by bioelectrical impedance analysis (BIA) between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  5. Fat-free mass

    by bioelectrical impedance analysis (BIA) between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  6. Muscle mass

    surfaces of the paraspinal and abdominal wall muscles at the level of L3-L4 disk space by CT for pancreatic cancer patients

    Time frame: at diagnosis

  7. Nutritional intake

    by 3-day food diary between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  8. Resting energy expenditure (REE)

    by indirect calorimetry between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  9. Appetite

    by visual analogue scale ranging from 0 to 100 mm between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  10. Appetite

    by fasting level of plasma ghrelin between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  11. Appetite

    by fasting level of plasma leptin between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  12. Appetite

    by fasting level of plasma glucagon-like peptide-1 (GLP-1) between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  13. Appetite

    by fasting level of plasma neuropeptide Y between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  14. Appetite

    by fasting level of plasma cholecystokinin between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  15. Homeostatic model assessment (HOMA)-score

    by fasting glycemia (mmol/l) and fasting insulinemia (mU/ml)) between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  16. Glycemia

    by fasting glycemia (mmol/l) between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  17. Insulinemia

    by fasting insulinemia (mU/ml) between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  18. Physical function

    by handgrip strength between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  19. Physical activity

    by the International Physical Activity Questionnaire (IPAQ) between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  20. Quality of life

    by the European Organisation for Research and Treatment of Cancer questionnaire (EORTC QLQ-C30) between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  21. Mortality

    by tumor progression between cachectic patients non-cachectic patients

    Time frame: at diagnosis

  22. Oral microbiota

    by 16SrRNA gene amplicon sequencing and metagenomic sequencing between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  23. Epithelial permeability

    by fasting levels of plasma zonulin between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  24. Epithelial permeability

    by fasting levels of plasma lipopolysaccharide-binding protein between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  25. Epithelial permeability

    by fasting levels of plasma glucagon-like peptide-2 between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  26. GALT function and systemic inflammation

    by fasting plasma level of C-reactive protein (CRP) and cytokines between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  27. GALT function and systemic inflammation

    by peripheral blood T regulatory cells (Tregs) levels and phenotype between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

  28. GALT function and systemic inflammation

    by myeloid derived suppressor cells (MDSC) levels and phenotype between cachectic patients non-cachectic patients and healthy volunteers

    Time frame: at diagnosis

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Apr 2025, 32 months after the start.

Of 318 non-industry observational studies under Pancreatic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 182. This study's planned 32 months is below that.

Counting every sponsor, half of 352 studies reached it within 60 months; a quarter within 34 and three quarters within 182.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2022
First posted
Nov 4, 2022
StartActual
Aug 1, 2022
Primary completionEst.
Apr 30, 2025
CompletionEst.
Apr 30, 2025
Last update
Dec 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05606523
Lead sponsor
Genton Graf Laurence
Responsible party
Genton Graf Laurence (Principal Investigator, University Hospital, Geneva) — Sponsor-investigator
First posted
Nov 4, 2022
Start date
Aug 1, 2022
Primary completion
Apr 30, 2025 (estimated)
Completion
Apr 30, 2025 (estimated)
Last update
Dec 6, 2024

Study contacts

Laurence Genton Graf, Prof
Contact
laurence.genton@hcuge.ch
+41 22 3729344
Alexandra Hemmer, MSc
Contact
alexandra.hemmer@hcuge.ch
+41795530491
Laurence Genton Graf, Prof
principal investigator · Geneva University Hospitals (HUG)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion